The Young Investigator program occupies a distinctive niche in the biomedical funding landscape. Federal grants increasingly favor established researchers with extensive preliminary data, leaving many talented scientists in the early stages of their careers struggling to secure support for bold, unproven ideas. By seeding high-potential projects at this critical juncture, the foundation functions as a kind of venture fund for psychiatric science, backing researchers whose work might otherwise never reach the point where larger institutional funders are willing to invest. Many of the field’s most influential figures, including Nobel laureates and leaders of major research institutions, received foundation support at the start of their careers.

Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, framed the new cohort as the vanguard of the field’s next generation. “BBRF Young Investigators represent a new generation of researchers who will pioneer breakthroughs in mental health research,” he said. “We are excited to be able to support the work of these young scientists, who will apply powerful new technologies and insights to understanding, treating, and curing mental illness.” His comments underscore the foundation’s long-standing bet that early investment in people, rather than narrowly defined projects, yields the greatest long-term returns for patients.

The 2026 awards span a strikingly broad range of psychiatric conditions. More than half of the funded projects, some 52 percent, are relevant to depression or schizophrenia, the two conditions that impose among the heaviest global burdens of disability. Significant numbers of grants also address anxiety disorders, addiction and substance-use disorders, autism spectrum disorders, post-traumatic stress disorder, bipolar disorder, attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, and suicide prevention. The breadth reflects a deliberate strategy of supporting the full landscape of brain and behavior research rather than concentrating resources on a single disease category.

Particularly notable is the emphasis on the earliest stages of human development. More than 30 projects, roughly one in six of the funded studies, focus on prenatal brain development or on childhood and adolescence. This concentration signals a growing recognition within psychiatry that the biological and environmental roots of mental illness often take hold long before symptoms appear in adulthood. Researchers funded in this cohort will examine how genetic, neurodevelopmental, and early-life environmental factors interact to shape trajectories of risk and resilience, work that could ultimately inform prevention strategies implemented decades before clinical illness emerges.

The methodological range of the portfolio is equally wide. Among the approaches being explored are new treatments for postpartum depression, including efforts to extend the benefits of rapid-acting therapies that have transformed care for some patients but whose effects can be short-lived. Other grantees will study psychedelic compounds such as psilocybin and 5-MeO-DMT, continuing a remarkable resurgence of scientific interest in substances long relegated to the margins of psychiatry. Additional projects will advance non-invasive brain stimulation techniques for depression and other disorders, and investigate how early-life stress may shape later vulnerability to mental illness, probing the neurobiological mechanisms through which adversity becomes biologically embedded.

Measured by research type, the 2026 class is weighted heavily toward fundamental discovery. Some 88 percent of the grants support basic research, the laboratory and theoretical work that builds the mechanistic foundation on which future treatments depend. Another 24 percent support research on next-generation therapies, while 17 percent advance diagnostic tools and early intervention, an area widely seen as critical given that psychiatric diagnoses are still largely based on clinical observation rather than objective biomarkers. A further 3 percent focus on new technologies. Because individual projects may span multiple categories, these figures overlap, but together they sketch a portfolio that balances long-horizon basic science with nearer-term clinical translation.

The global composition of the cohort highlights the international character of contemporary neuroscience. Seventy-nine percent of the grantees are based in the United States, while 21 percent come from 15 other countries, bringing perspectives and research infrastructures from across the world to bear on shared questions about the brain. This distribution also reflects the reality that mental illness respects no borders: depression, schizophrenia, anxiety, and addiction affect hundreds of millions of people worldwide, and advances made in laboratories on any continent may translate into benefits everywhere.

Judith M. Ford, Ph.D., President of the BBRF Scientific Council and Co-Chair of the Young Investigator Grant Selection Committee, emphasized the humanitarian stakes of the program. “BBRF Young Investigator grants fund groundbreaking research aimed at reducing suffering in people with mental illness,” she said. “These early-career scientists are pushing the boundaries in basic and clinical research to establish new approaches to early prediction, prevention, and intervention and to develop next-generation therapies that offer hope for those with brain and behavior illnesses.” Her words capture the dual promise of the program: scientific discovery paired with a direct commitment to patients whose conditions remain inadequately treated.

The foundation’s cumulative record gives weight to that promise. Since 1987, it has awarded more than $487 million to fund more than 5,900 leading scientists around the world, making it one of the largest private funders of mental health research. Its financial model, in which 100 percent of every dollar donated for research is invested in research while operating expenses are covered by separate foundation grants, has allowed it to sustain this support across decades of shifting funding climates. The organization also produces the Emmy-nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which works to remove the stigma of mental illness and convey the message that with help, there is hope. A full list and summaries of the 2026 Young Investigator projects are available in the foundation’s 2026 Young Investigator Grants booklet, offering a detailed window into where the next generation of psychiatric science is headed.

Subject of Research: Young Investigator grant awards supporting early-career mental health research

Article Title: Brain & Behavior Research Foundation awards 180 young investigator grants to advance mental health research

Article References: Brain & Behavior Research Foundation awards 180 young investigator grants to advance mental health research. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Brain & Behavior Research Foundation, Young Investigator grants, mental health research, depression, schizophrenia, psychedelics, brain stimulation, early intervention, neuroscience funding, postpartum depression, suicide prevention, early-career scientists